Mulnitorsen is under clinical development by Andes Biotechnologies and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase I drugs for Colorectal Cancer have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Mulnitorsen’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Mulnitorsen overview

Andes-1537 is under development for the treatment of relapsed and refractory solid tumors including bladder cancer, pancreatic cancer, cholangiocarcinoma, colorectal cancer, gallbladder adenocarcinoma, cervical cancer, gastric adenocarcinoma. It is administered by subcutaneous injection. The drug candidate is an antisense oligonucleotide.

It was under development for renal cell carcinoma.

For a complete picture of Mulnitorsen’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.